Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
07 March 2025 - 9:20AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of March 2025
Commission
File Number: 001-42527
Basel
Medical Group Ltd
6
Napier Road,
Unit
#02-10/11 Gleneagles Medical Centre
Singapore
258499
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Publicly
Tradable Shares
On
February 26, 2025, Basel Medical Group Ltd (the “Company”) closed its initial public offering (the “IPO”) of
2,205,000 ordinary shares, no par value (the “Ordinary Shares”). The Company completed the IPO pursuant to its registration
statement on Form F-1 (File No. 333-282096) (the “Registration Statement”), which was initially filed with the U.S. Securities
and Exchange Commission (the “SEC”) on September 13, 2024, as amended, and declared effective by the SEC on February 18,
2025. The Registration Statement also registered 2,000,000 Ordinary Shares for resale by certain selling shareholders in a resale prospectus.
As of March 6, 2025, the number of publicly tradable shares of the Company is 4,205,000 Ordinary Shares.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Basel Medical Group Ltd |
|
|
|
|
By: |
/s/ Raymond
Wai Man Cheung |
|
Name: |
Raymond Wai Man Cheung |
|
Title: |
Chief Executive Officer and Director |
|
|
|
|
Date: |
March
6, 2025 |
|
Basel Medical (NASDAQ:BMGL)
Historical Stock Chart
From Feb 2025 to Mar 2025
Basel Medical (NASDAQ:BMGL)
Historical Stock Chart
From Mar 2024 to Mar 2025